| Literature DB >> 30857245 |
Cristina Mas-Bargues1, Jorge Sanz-Ros2, Aurora Román-Domínguez3, Marta Inglés4, Lucia Gimeno-Mallench5, Marya El Alami6, José Viña-Almunia7, Juan Gambini8, José Viña9, Consuelo Borrás10.
Abstract
The key hallmark of stem cells is their ability to self-renew while keeping a differentiation potential. Intrinsic and extrinsic cell factors may contribute to a decline in these stem cell properties, and this is of the most importance when culturing them. One of these factors is oxygen concentration, which has been closely linked to the maintenance of stemness. The widely used environmental 21% O₂ concentration represents a hyperoxic non-physiological condition, which can impair stem cell behaviour by many mechanisms. The goal of this review is to understand these mechanisms underlying the oxygen signalling pathways and their negatively-associated consequences. This may provide a rationale for culturing stem cells under physiological oxygen concentration for stem cell therapy success, in the field of tissue engineering and regenerative medicine.Entities:
Keywords: aging; environmental oxygen concentration; physiological oxygen concentration; physioxia; redox; senescence
Mesh:
Substances:
Year: 2019 PMID: 30857245 PMCID: PMC6429522 DOI: 10.3390/ijms20051195
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Oxygen partial pressure in tissues.
Figure 2Benefits of low oxygen tension on stem cells behaviour. HIF-1α implication is shown in red. Abbreviations: HIF-1α: hypoxia inducible factor 1α; ROS: reactive oxygen species; HO-1: Heme Oxygenase 1; Nrf2: nuclear receptor factor 2; GSH/GSSG: glutathione ratio; OXPHOS: oxidative phosphorylation; LDH: lactate dehydrogenase; PDK: pyruvate dehydrogenase kinase; MAPK: mitogen activated protein kinase; PI3K: phosphoinositide 3 kinase; ERK: extracellular signal regulated kinase; VEGF: vascular endothelial growth factor; OSKM: Oct3/4, Sox2, Klf4 and c-Myc; HIF: hypoxia inducible factor.
Summary of relevant studies on stem cells alterations at different oxygen tensions.
| Cell Type | Oxygen Conditions | Duration | Affected Parameters | Ref. |
|---|---|---|---|---|
| C2C12 myoblasts | 6% vs. 21% | 72 h | ROS production, differentiation | [ |
| HSCs (CD34+ cells) | 5% vs. 21% | 7 days | ROS levels, antioxidant enzymes (SOD, CAT and GPx), glutathione redox state | [ |
| Human Dermal Fibroblasts (HDFs) | 5% vs. 21% | 72 h | ROS production, enzymatic and non-enzymatic antioxidant response system, DNA damage, extracellular matrix (ECM) proteins | [ |
| DPSCs | 3% vs. 21% | Up to passage 25 | Oxidative stress parameters (ROS, MDA, carbonylation, antioxidant defenses), proliferation, stemness (OSKM) | [ |
| MSCs from adipose tissue | 3% vs. 20% | Up to 22 passages | Genetic stability, glycolytic function, cell differentiation and ROS production and targets (Protein carbonylation and MDA) | [ |
| NSCs | 3% vs. 21% | 10 days | Survival, renewal potential and differentiation | [ |
| BMSCs | 2% vs. 20% | 12 days | Proliferation kinetics, metabolism, differentiation potential | [ |
| BMSCs | 1% vs. 21% | 7 days | Proliferation, migration, morphology, adhesion molecules, osteogenic differentiation | [ |
| MSCs from umbilical cord | 1.5%, 2.5%, 5%, 21% | 70 h | Proliferation, metabolism, pH, oxygen consumption | [ |
| ADSCs | 1% vs. 20% | 72 h | Proliferation, ROS generation, migration, OSKM | [ |
| Muscle Precursor Cells (MPCs) | 5%, 10%, 15%, 20% | Up to passage 2 | Cell cycle regulation (p21 and p27), Proliferation | [ |
| BM-MSCs and ADSCs | 2% vs. 21% | Up to passage 10 | Morphology, differentiation potential, genomic stability, telomere length, mitochondrial membrane potential, ATP content | [ |
| Central Nervous System (CNS) Precursor Cells | 2%, 5%, 20% | Up to passage 2 | Proliferation, HIF1α, apoptosis, multilineage differentiation potential | [ |
| MSCs from umbilical cord | 3% vs. 21% | Up to passage 12 | Proliferation, HIF1α, ERK signalling pathway, stemness (OCT3/4 and Nanog), p21, p16, p53 | [ |
| BM-MSCs | 5% vs. 21% | Up to passage 15 | Donor age, differentiation potential, SA-β-Gal, miRNA sequencing, KEGG signalling pathways | [ |
| BM-MSCs | 1% vs. 21% | Up to passage 4 | Migration, proliferation, apoptosis, differentiation potential, PTEN-PI3K/AKT signalling pathway, miRNAs, HGF and VEGF | [ |
| Satellite Cells | 1% vs. 21% | 48 h | Quiescence, self-renewal, miRNAs, Notch signalling pathway, transplantation efficiency | [ |
| CSCs | 0.5%, 5%, 21% | Up to passage 10 | Proliferation, survival, migration, SA-β-Gal, apoptosis | [ |
| MSCs from umbilical cord | 2.2% vs. 21% | 24 h | ROS levels, migration, HIF1α, VEGF | [ |
| ESCs | 1–5% vs. 21% | Up to passage 50 | Morphology, colony growth, differentiation, hGC production, embryoid body formation | [ |
| ESCs | 4% vs. 20% | Up to passage 50 | Morphological differentiation, microarray and transcriptome profiling, HIF, stemness | [ |
| Neural Crest Stem Cells | 5% vs. 20% | 12 days | Survival, proliferation, multilineage differentiation | [ |
| BM-MSCs | 1, 3, 5, 10% vs. 21% | 7 days | Viability, proliferation, self-renewal, osteogenic differentiation | [ |
| C2C12 myoblasts, Satellite Cells and NSCs | 1% vs. 21% | 7 days | Notch signalling pathway, undifferentiated state maintenance | [ |
| BM-MSCs and HSCs | 5, 12, 20% | 10 days | ROS content, proliferation, directional differentiation, apoptosis, cell cycle, migration | [ |
| BM-MSCs | 2% vs. 18% | 2 weeks | Osteogenic and adipogenic differentiation, HIF1α, VEGF | [ |
| BM-MSCs | 1% vs. 21% | 7 days/4 weeks | Proliferation, migration, stemness (OCT3/4, Nanog, SALL4, KLF4), differentiation | [ |
| MSCs | 2% vs. 20% | 7 days | Proliferation, osteogenic differentiation | [ |
| BM-MSCs | 0.2% vs. 21% | 7 or 14 days | Osteogenic and adipogenic differentiation, HIF1α | [ |
| MSCs | 1, 2, 3, 4, 6% vs. 21% | 2, 4, 8, 24, 48, 72 h | Adipogenic differentiation | [ |
| BM-MSCs | 3% vs. 21% | Isolation and expansion (4 weeks) | Chondrogenic differentiation, cell surface markers, ECM formation, expansion, HIFs | [ |
| BM-MSCs | 2% vs. 20% | 14 days | Chondrogenic differentiation | [ |
| MSCs | 1% vs. 21% | 21 days | Osteogenic differentiation, HIFs | [ |
| WJ-MSCs | 3% vs. 21% | Up to passage 13 | Growth kinetics, SA-β-Gal, differentiation, HIFs, p16, p21, p53, karyotype | [ |
| ADSCs | 1% vs. 21% | Up to passage 2 | Proliferation, multilineage differentiation, stemness (Nanog, SOX2) | [ |
| ESCs (dorsal pancreatic bud) | 3%, 8%, 21% | 24h or 7 days | Cell differentiation, HIF1α gene and protein expression | [ |
| ESCs | 3–5% vs. 20% | Up to passage 3 | Morphology, proliferation, pluripotency (SOX2, Nanog and OCT3/4), HIFs | [ |
| BM-MSCs | 1% vs. 21% | 14 days | Proliferation, differentiation, self-renewal | [ |
| WJ-MSCs | 5% vs. 21% | 2-4 weeks | Proliferation, stemness (OCT3/4, Nanog, REX1 and SOX2), HIFs, differentiation | [ |
| BM-MSCs | 5% vs. 21% | Up to passage 2 | Morphology, differentiation, transcriptional profiling, metabolism, adhesion | [ |
| Dermal Fibroblasts into IPSCs | 1%, 5%, 21% | 40 days | Efficiency of reprogramming into iPSCs (ESC markers, teratoma formation) | [ |
| Fibroblasts, ESCs and IPSCs | 2%, 5%, 21% | 2 weeks | Reprogramming efficiency, HIFs, metabolism (OCR and ECAR) | [ |
Abbreviations: HSC: haematopoietic stem cell; HDF: human dermal fibroblast; DPSC: dental pulp stem cell; MSC: mesenchymal stem cell; NSC: neural stem cell; BMSC: bone marrow stem cell; ADSC: adipose derived stem cell; MPC: muscle precursor cell; BM-MSC: bone marrow mesenchymal stem cell; CNS: central nervous system; CSC: cardiac stem cell; ESC: embryonic stem cell; WJ-MSC: Wharton Jelly mesenchymal stem cell; iPSC: induced pluripotent stem cell.